Filtered By:
Procedure: Hemodialysis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 19521 results found since Jan 2013.

In search for a biochemical marker of overhydration in hemodialysis: the "magic bullet" yet to be found.
Authors: Stompór T, Winiarska A PMID: 26266684 [PubMed - in process]
Source: Polskie Archiwum Medycyny Wewnetrznej - August 15, 2015 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis
CONCLUSIONS: Currently, there is no available high certainty evidence to support one treatment over another for CRBSIs. The benefit of using ethanol lock treatment in combination with systemic antibiotics compared to systemic antibiotics alone for CRBSIs in patients receiving maintenance HD remains uncertain due to the very low certainty of the evidence. Hence, further RCTs to identify the benefits and harms of CRBSI treatment options are needed. Future studies should unify CRBSI and cure definitions and improve methodological design.PMID:35363884 | PMC:PMC8974891 | DOI:10.1002/14651858.CD013554.pub2
Source: Cochrane Database of Systematic Reviews - April 1, 2022 Category: General Medicine Authors: Beatriz M Almeida Daniel H Moreno Vladimir Vasconcelos Daniel G Cacione Source Type: research

Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
CONCLUSIONS: Given the low-certainty evidence, we are uncertain whether intermittent locking with heparin results in fewer central venous catheter occlusions than intermittent locking with normal saline in adults. Low-certainty evidence suggests that heparin may have little or no effect on catheter patency duration. Although we found no evidence of differences in safety (CVC-related bloodstream infections, mortality, or haemorrhage), the combined studies were not powered to detect rare adverse events such as heparin-induced thrombocytopaenia. Further research conducted over longer periods would reduce the current uncertain...
Source: Cochrane Database of Systematic Reviews - July 18, 2022 Category: General Medicine Authors: Eduardo L ópez-Briz Vicente Ruiz Garcia Juan B Cabello Sylvia Bort-Mart í Rafael Carbonell Sanchis Source Type: research

Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
CONCLUSIONS: Tenapanor is the first drug in its class that lowers hyperphosphatemia in ESKD patients through a novel mechanism of action involving paracellular inactive transport. Although more studies are needed, early results indicate that tenapanor may have a place in managing hyperphosphatemia in ESKD patients both as monotherapy and as an adjunct to existing phosphate binder therapy.PMID:35041802 | DOI:10.18433/jpps32284
Source: J Pharm Pharm Sci - January 18, 2022 Category: Drugs & Pharmacology Authors: Tiffany Lin Akram Al-Makki Brian Shepler Source Type: research